Long-Term Low-Dose Aspirin Linked With Reduced Cancer Risk
Long-term low-dose aspirin use is associated with slight to moderate reductions in the risk of specific cancers, but not cancer overall.
Read More
Oncology
ECOG Performance Status Linked With Survival in NSCLC
In metastatic NSCLC patients receiving immunotherapy, racial/ethnic groups have similar outcomes; ECOG performance status correlates with survival.
Read More
10-Year Lung Cancer-Specific Survival for Low-Dose CT Persists
Two decades of annual low-dose CT screening in the I-ELCAP cohort reveal a sustained 80% lung cancer-specific survival rate, updating the cure rate.
Read More
Tabelecleucel is a therapeutic option for EBV-related post-transplant lymphoproliferative disease
1. Tabelecleucel provided clinical improvement in patients with EBV-related post-transplant...
Read More
Penetrating traumatic brain injuries associated with greater risk of brain cancer amongst veterans
1. Among United States veterans of the Iraq and Afghanistan wars, the experience of a moderate,...
Read More
Presence of unmet social needs associated with lower utilization of breast cancer screening programs
1. Having a greater number of unmet social needs was associated with lower utilization of...
Read More
Enobosarm in AR-positive, ER-positive, and HER2-Negative Advanced Breast Cancer
1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group. 2. Grade 3 or...
Read More
Tabelecleucel Shows Promise as Therapeutic Option for EBV-Related Post-Transplant Lymphoproliferative Disease
This phase 3 multicenter trial demonstrated the efficacy and safety of tabelecleucel in patients...
Read More
Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care...
Read More
Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases
1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the...
Read More
Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease
1. In patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC), immune...
Read More
Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone)...
Read More
Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma
1. The objective response rate was 28% with a complete response of 5.6% and a partial response of...
Read More
Atezolizumab in addition to bevacizumab and platinum-based chemotherapy improves survival in metastatic cervical cancer
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival...
Read More
Worse breast cancer death rates for non-screen detected ductal carcinoma situ
1. Women with non-screen detected ductal carcinoma in situ had worse outcomes for the 25 years...
Read More
Preserving Pulmonary Function’s Clinical Impact Following Lung Resection in Early-Stage NSCLC
The following is a summary of “Clinical significance of preserving pulmonary function after lung...
Read More
Mirtazapine improves caloric intake compared to placebo in patients with advanced non-small cell lung cancer
1. While perceived appetite did not differ between study groups, patients receiving mirtazapine...
Read More
Low dose olanzapine in non-inferior to standard dose in terms of anti-emetic effect in patients receiving emetogenic chemotherapy
1. Low dose Olanzapine (2.5 mg) demonstrated similar anti-emetic effect to standard dose...
Read More
Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2....
Read More
Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall...
Read More